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Abstract: Human cytomegalovirus (CMV) is a leading cause of congenital infections worldwide Women infected for the 
first time during pregnancy are especially likely to transmit CMV to their fetuses and has been proposed as a risk factor 
for preterm birth. The seroprevalence of CMV in adults and the incidence of congenital CMV infection are highest in 
developing countries (1 to 5% of births) 90% of infected infants are asymptomatic at birth and are not recognized as at 
risk for CMV-associated infection. This study was carried out to determine the prevalence rate of CMV infection among 
pregnant women attending an antenatal clinic. In this study, Two-hundred and eighty eight (288) pregnant women were 
enrolled. Questionnaires were issued to volunteer subjects after due consent was sought, to determine demographic and 
other relevant data. 5mls of blood was collected by venous puncture from the antecubital fossa and dispensed into plain 
containers; sera were collected after centrifugation of the blood. Sera obtained were screened for the presence of CMV 
(IgM) antibodies using ELISA technique (Clinotec Laboratories Canada).Result showed that out of the 288 women 
tested, 54 (18.8%) were positive for CMV antibodies while 234 (81.2%) tested negative. With regards to age group 
distribution, women within 15 – 20 years had a prevalence rate of 4.5%, 21 – 30 years both had 3.5%, 31 – 35 had 3.1%, 
36 – 40 years had 1.3% while 41 – 45 years had a prevalence rate of 2.8%, all the age groups had no statistical significant 
(P>0.05) result. With regards to trimester of the volunteer subjects screened, 1st, 2nd and 3rd trimester subjects recorded a 
prevalence rate of 3.1%, 9.4% and 6.2% respectively which was statistically significant (P0.05).Occupational status of 
subjects studied recorded  no statistical significant (P0.05) result obtained showed that unemployed subjects recorded a 
prevalence of 5.6% compared to the self-employed with 4.9%, farmers recorded 3.8%, while students had a prevalence of 
1.7% however subjects who are civil servants recorded a prevalence of 2.8%. Location of volunteer subjects studied 
showed that pregnant in rural areas had a prevalence rate of 12.2% while those living in urban areas recorded 6.6% 
prevalence without any statistical significant (P0.05).Records from this study indicates the of presence of CMV (Igm) 
antibodies amongst the subjects screened. Hence the need for early detection of the virus in pregnant women. 
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INTRODUCTION 
CMV is a host-restricted member of the 
Herpesviridae family of viruses [1]. Primary infection is 
characterized by a period of active virus replication 
with virus shedding in saliva, urine, milk, and genital 
secretions, a viremic phase, and, in some, an infectious 
mononucleosis syndrome [1, 2]. This is followed by the 
development of a broad immune response involving all 
arms of the adaptive immune system, and after several 
weeks, viral latency is established[1].The disease is 
usually asymptomatic, and is found universally 
throughout all geographic locations and socio-economic 
groups although it is more common in developing 
countries and areas of lower socio-economic conditions 
[3]. In immunocompetent mothers, reactivation of 
endogenous virus and/or reinfection with new strains 
occurs periodically, and DNAemia and viruria may be 
present in both [2] Indeed, CMV causes more cases of 
congenital disease than the combination of 29 currently 
screened conditions in most American states [4] and is 
more common than several disorders included in 
newborn screening in European Union countries [5]. 
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 CMV can be shed in various bodily 
secretions, particularly urine and saliva [6]. CMV is 
transmitted person-to-person via close non-sexual 
contact, sexual activity, breastfeeding, blood 
transfusions, and organ transplantation [6]. For pregnant 
women, important sources of infection include sexual 
activity and contact with the urine or saliva of young 
children, especially their own children [7].Intrauterine 
CMV infection occurs in approximately 1% of all live 
births, with up to 15% of congenitally infected infants 
showing symptoms at birth [8,9,10]. These symptoms 
include any combination of microcephaly, intracranial 
calcification, chrioretinitis, jaundice, low birth weight, 
hepatosplenomegaly and purpura [11]. The mortality 
rate among symptomatic infants can be as high as 30%; 
these symptomatic infants who survive are likely to 
develop long-term neurologic sequelae including 
hearing loss, visual impairment, psychomotor delay and 
mental retardation [11]. 
 
The risk for long-term outcomes appears to be 
highest in infants born to mothers with primary 
infection in the first half of pregnancy [12, 13]. 
Following first-trimester maternal CMV infections, 
about a quarter of infants (20 to 25%) who are 
congenitally infected will develop sensor neural hearing 
loss (SNHL), and 30 to 35% will suffer some form of 
central nervous system (CNS) sequelae [13]. However, 
maternal CMV reactivation or reinfection with a 
different CMV strain can also lead to fetal infection 
[14]. Approximately 10 percent of congenitally infected 
infants are symptomatic at birth, and of the 90 percent 
who are asymptomatic, 10–15 percent will develop 
symptoms over months or even years [14].Recent 
studies report lower transmission rates in early 
pregnancy (in comparison to later gestation)[15,16], 
with maternal primary infection leading to infection in 
30 to 35% of fetuses and nonprimary infection having a 
transmission rate of 1.4% in study populations 
predominantly from industrialized countries (1.1 to 
1.7%) [17]. Data from screened populations indicate 
that while only one in 10 newborns infected in utero 
have obvious clinical signs of congenital infection 
[18,19] 10% to 15% of those without clinical findings 
(here referred to as having symptomatic and 
asymptomatic congenital CMV infection, respectively) 
develop long-term neurological sequelae [19].Although, 
exposure to young children and sexual activities have 
been linked with increased risk of CMV, it is unlikely 
that avoidance of either of these activities will be a 
practical means of preventing CMV infection for 
women of childbearing age. Maternal (prenatal) 
screening may permit early identification of at-risk 
pregnancies or infected infants and thus the use of 
interventions to reduce morbidity has attracted 
increasing interest in recent years [20]. The majority of 
congenital CMV infections are asymptomatic at birth, 
and the diagnosis of intrauterine infection relies on 
virus detection by culture-based methods or PCR. 
Saliva or urine specimens should be obtained within the 
first 2 weeks of life [21]. Studies have revealed that 
Cytomegalovirus is found throughout all geographic 
locations and infect between 50% and 80% of adults in 
the United States as indicated by the presence of 
antibodies in much of the general populations [22].In 
Nigeria, a study conducted in 2008, reported a 
prevalence of 45.0% and 33% IgM antibodies among 
breastfeeding mothers and of the infants [23]. Similarly, 
Okwori et al.; in a study among expectant mothers in 
Bida, Nigeria, reported IgG antibodies prevalence of 
86.1% among multigravid women and 77.1% among 
primigravid women [24]. 
 
MATERIALS AND METHOD 
Study design 
The study was a cross sectional study which 
lasted for three months. Data was collected from 
consenting volunteers after obtaining due ethical 
permits from the relevant bodies.  
 
Study area and study Population 
The study was carried out among pregnant 
women attending antenatal clinic at Specialist Hospital 
Gombe. These were the inclusive criteria while non-
pregnant women were excluded from the study. The 
population used for this study was two hundred and 
eighty eight (288) pregnant women whose ages range 
between 15 and 45 years.   
 
Sample collection and processing 
A well-structured questionnaire was used to 
obtain bio data and risk factors from the pregnant 
women screened. Five (5mls) of blood was collected 
aseptically by venipuncture from the volunteer subjects 
according to the method of [25].Sera obtained were 
separated, dispensed into a clean container and stored at 
-200C until they were ready for the assay. 
 
Test methodology 
Sera samples were screened for the presence of 
CMV IgM antibodies using Enzyme linked 
immunosorbent Assay (ELISA) Diagnostic Antigen kit 
by Clinotec Laboratories.  
 
Principles 
Cytomegalovirus antigens are fixed to the 
interior surface of microwells, patient’s serum is added 
and any antibody present to CMV will bind to these 
antigens. The microwells are washed to remove 
unbound serum proteins. Antibodies conjugated with 
Horse radish peroxidasae enzyme are directed against 
human 1gM are added and will in turn bind to any 
human 1gM present. The microwells are washed to 
remove unbound conjugate and then 
chromogen/substrate is added. In the presence of 
peroxidase enzyme, the colourless substrate is 
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hydrolyzed to a coloured end product. The colour 
intensity is proportional to the amount of antibodies 
present in the patient’s serum. 
 
PREPARATION FOR ASSAY 
All reagents were brought to room temperature 
and gently mixed. The wash buffer was diluted (1:30) 
with distilled water and mixed well.   
 
Assay Procedure: 
A 1:51 dilution of sample was done by adding 
5l of test sample to 250l of sample diluents into 
separate tubes. Using a multichannel pipette 100l of 
prediluted negative control, positive control, calibrated 
(prediluted by the manufacturer) and each diluted 
sample was transferred from the tubes to the wells. The 
wells were covered and incubated at 37oC for 30 
minutes. The wells were vigorously shaken to move out 
liquid and each well were washed 5 times with 250 - 
300l diluted wash buffer 100l of Horse Radish 
Peroxidase (HRP) conjugate was added to each well 
and incubated for 30minutes at 37oC. The wells were 
washed 5 times again with 250 - 300l diluted wash 
buffer after removing excess liquid and 100l of TMB, 
substrate solution was added to each well and incubated 
for 10minutes at room temperature. 100l of stop 
solution was added to each well and gently shaken; the 
absorbance of each well was read at a wavelength of 
540nm with the aid of an Elisa technique assay. 
 
RESULTS  
 Out of the 288 sera samples screened, 54 
(18.8%) tested positive while 234 (81.2%) tested 
negative. Table 1. The distribution of human CMV with 
respect to age group showed that women within the age 
group of 15 – 20 years had the highest prevalence rate 
of 13( 4.5%) followed by those within the age range of 
21 -25 years with 109(3.5%) prevalence. Subjects 
within 26-30 years of age recorded a prevalence of 
10(3.5%). Women within 31 – 35 years had 
9(3.1%).While those within 36-40 years of age recorded 
a prevalence of 4(1.3%) as compared to subjects aged 
41 – 45years with a prevalence of 1.4%. Table 2 
 
Table 1: Overall result of HCMV (Igm) Screening 
No. of 
Samples 
No. Positive % Positive No. Negative % 
Negative 
P- value 
 
288 
 
54 
 
18.8% 
 
234 
 
81.2% 
 
0.317(P0.05) 
 
Total 
 
288 
 
54 
 
18.8% 
 
81.2% 
 
 
Table 2: Distribution of HCMV based on age group (years) 
Age group No of samples No Positive % Positive P-value 
15 – 20 
21 – 25 
26 – 30 
31 – 35 
36 – 40 
41 – 45 
59 
73 
68 
52 
24 
12 
13 
10 
10 
9 
4 
8 
4.5% 
3.5% 
3.5% 
3.1% 
1.3% 
2.8% 
0.145(P0.05) 
0.145(P0.05) 
0.279(P0.05) 
0.698(P0.05) 
0.560(P0.05) 
0.060(P0.05 
 
Total 
 
 
288 
 
54 
 
18.8% 
 
 
Distribution in relation to gestational age of 
the women showed that those in their second (2nd) 
trimester recorded the highest seroprevalence of 
27(9.4%) followed by those in their third (3rd) trimester 
with 18(6.2%) and lastly those in their first (1st) 
trimester with 9(3.1%). Table 3. 
 
Table 3: Distribution of HCMV with respect to gestational Age of the women 
Trimester No of 
samples 
No. Positive % Positive P-value 
1st Trimester 
2nd Trimester 
3rd Trimester 
23 
149 
116 
9 
27 
18 
3.1% 
9.4% 
6.2% 
0.016(P0.05) 
0.016(P0.05) 
0.008(P0.05) 
 
Total 
 
288 
 
54 
 
18.8% 
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Distribution based on occupational status of 
the women showed that those who are unemployed had 
the highest prevalence of 16(5.6) followed by those 
who are self-employed with 14(4.9%). Civil servants 
had 8(2.8%), farmers 11(3.8%) and students recorded 
the lowest prevalence of 5(1.7%). Table 4. 
 
Table 4: Distribution of HCMV in relation to occupation 
Occupation No of 
samples 
No 
Positive 
% Positive P-value 
Civil Servant 
Students 
Farmers 
Self employed 
Unemployed 
81 
29 
27 
68 
83 
8 
5 
11 
14 
16 
2.8% 
1.7% 
3.8% 
4.9% 
5.6% 
0.666(P0.05) 
0.666(P0.05) 
0.066(P0.05) 
0.277(P0.05) 
0.352(P0.05) 
 
Total 
 
288 
 
54 
 
18.8% 
 
 
Women who reside in rural areas had a 
prevalence rate of 35(12.2%) compared to a prevalence 
rate of 19(6.6%) in those who reside in urban areas. 
Table 5 
 
Table 5: Distribution of HCMV in relation to geographical location 
Geographical Location No of 
samples 
No 
Positive 
% Positive P-value 
 
Urban 
Rural 
 
201 
87 
 
19 
35 
 
6.6% 
12.2% 
 
0.718(P>0.05) 
0.259(P>0.05) 
 
Total 
 
288 
 
54 
 
18.8% 
 
 
DISCUSSION  
From the results obtained in this study, 
prevalence rate showed that over 18% of the women 
tested were seropositive for CMV (IgM) antibodies 
while 81% were seronegative. The result obtained in 
this study differs from work of Munro, et al.; [26] who 
recorded a low prevalence rate of 5.5% among pregnant 
women in Australia. Arakpour, et al.; [27] equally 
recorded a low prevalence rate of 5.4% in women of 
childbearing age in a study conducted in Iran while 
Kassim, et al.; [28] recorded a higher prevalence of 
45% among Nigerian mothers.  
 
The difference in prevalence rates could be 
attributed to differences in geographical locations, 
socio-economic status and strata of the women at 
various locations where the studies/research was carried 
out [29]. In a similar studies carried out in Kaduna State 
by Edward et al.; [30] a prevalence of 10.5% was 
recorded which is lower than what obtains in this study. 
 
From this finding a high prevalence was 
observed among all the age groups. However, the low 
prevalence rates recorded among those aged 36 – 45 
agrees with the fact that the rate of CMV (Igm) 
prevalence decreases with advance in age [31]. 
similarly in the work of Ndako et al.; [32] Age 
variation showed the highest prevalence rate of 14.7% 
among pregnant women aged of 20-34 years (χ 2 = 
1.333, P>0.05).Moreso, the increase in seroprevalence 
with age as adduced in other studies, is due to the fact 
that majority of the women have already been exposed 
and recovered from primary infection by the time they 
reach childbearing age 
 
The high prevalence rates seen among subjects 
aged, 15 – 30 years could also be attributed to the fact 
that subjects within this age group are among the 
sexually active age hence the likelihood of being 
infected through the sexually transmitted route 
[32].This also agrees with the work of [33] that the 
prevalence of CMV infection is higher among women 
attending clinics for sexually transmitted diseases and 
also among sexually active adolescents. 
 
Our findings showed that subjects in their 
second trimester of pregnancy recorded the highest 
prevalence followed by those within the third trimester 
and lastly those in first trimester. However the result 
obtained from all trimesters are statistically significant 
χ2=0.016 ;(P0.05).The result obtained in this study 
with regards to gestational period agrees with the work 
of Okwori et al.; [34] where Pregnant women in their 
second trimester showed the highest seroprevalence 
(86.2%) of Cytomegalovirus antibodies followed by 
subjects in their third trimester with 75.9% prevalence 
[24]. This result from our study is however is in 
contrast with the result obtained by [30] where women 
at their third trimester have the highest prevalence of 
12.5% followed by the first and second trimester with 
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prevalence of 11.1% and 9.7% respectively (P>0.05) 
Women at all stages of pregnancy could be at high risk 
of intrauterine transmission but those at higher risk are 
those who were infected within the first 20 weeks of 
pregnancy [34, 35]. Babies born to these women in their 
second trimester are at risk of getting congenital CMV 
infection [36]. 
 
This poses a serious threat to the foetus in 
utero as stated in the report of [36] that women infected 
with CMV during late gestation are more likely to 
transmit the virus to their unborn babies compared to 
women who are infected at early gestation. Similarly, 
high rates observed amongst subjects at the second and 
third trimesters could be as a result of advancement in 
foetal age making such women heavier and careless to 
personal hygiene thereby predisposing them to infection 
and a high risk of intrauterine transmission [37]. 
 
Occupational distribution of subjects showed 
that there was no association between maternal 
immunity and social class. The rate of prevalence seen 
in all the groups were not statistically significant 
(P>0.05) but high percentages seen in the unemployed, 
farmers and self employed could be due to the fact that 
CMV infection is most likely acquired among those at 
the lower socio-economic strata in developing countries 
(Jawetz, et al 2007).This finding agrees with a previous 
study, which demonstrated that CMV infection was 
higher in the lower socioeconomic class [38, 39].  
 
High prevalence rate was recorded among 
women living in rural areas compared to those living in 
urban areas, though the prevalence were not statistically 
significant (P>0.05), it is however in accordance with 
the work documented by [3, 29] that although 
prevalence of CMV infection increases within every 
group, the overall prevalence of infection and the age of 
initial acquisition of the virus varies greatly according 
to living environment of the individuals. Antibody 
prevalence may be moderate in 40 – 70% of adults 
found among the high socio-economic groups in 
developed countries in contrast to a prevalence rate of 
90% in children and adults living in underdeveloped 
nations and in low socio-economic groups  
 
The greatest risk connected to CMV is the 
probability of congenital defects. Congenital infection 
occurs in foetus if the mother has a primary infection or 
reactivation during pregnancy. A Clinical symptom of 
this takes the form of severe generalized or cytomegalic 
inclusion disease in which the infants usually have 
jaundice, hepatosplenomegaly, thrombocytopenia, 
haemolytic anaemia. The brain is almost always 
involved with microcephaly and motor disorder. Most 
infants with these symptoms do not survive. Infants are 
usually deaf and mentally retarded [40]. 
 
CONCLUSION 
In conclusion, reports obtained from this work 
showed the presence of CMV (IgM) antibodies amongst 
the pregnant women screened, thereby indicating a 
current infection and likelihood of transmission in 
utero. Since the seroprevalence of CMV infection 
increases with lower socio-economic status of 
individual subjects coupled with the risk of intrauterine 
transmission with advance in the gestational age of 
pregnant women, thereby making the tendency of 
transmitting the virus in utero high, calls for an urgent 
need for women of childbearing age to be early 
diagnosed. Since the resultant congenital infection 
could be asymptomatic or symptomatic. Asymptomatic 
infants serve as a source of infection to other children 
and those handling them could still develop clinical 
sequelae later in life. This calls for closer monitoring 
among this group as they grow, so as to decrease the 
rate of transmission and infection within the population. 
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